Peptides are selective and efficacious signaling molecules that bind to specific cell surface receptors to trigger intracellular effects.
The global peptide therapeutics market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.
Global Peptide Therapeutics Market: Drivers
Increasing prevalence of metabolic diseases and cardiovascular disorders (CVDs) is expected to boost growth of the global peptide therapeutics market over the forecast period. For instance, according to American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. are suffering from some form of CVD or the after-effects of stroke.
Moreover, increasing healthcare expenditure is also expected to aid in growth of the market. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5% per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027.
North America region held dominant position in the global peptide therapeutics market in 2018, accounting for 42.1% share in terms of value, followed by Europe.
Global Peptide Therapeutics Market: Restraints
Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides are expected to hinder growth of the global peptide therapeutics market.
Moreover, presence of stringent safety regulations is also restraining the market growth. Pharmaceuticals products such as peptide therapeutics require better regulatory framework as these treat multiple pathological conditions; by 2020, the regulatory framework is expected to be better.
Global Peptide Therapeutics Market: Opportunities
R&D of new peptides is expected to offer lucrative growth opportunities for players in the market. For instance, in December 2019, CohBar, Inc. announced new preclinical data that confirmed the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF).
Moreover, R&D in microbiome research is also expected to boost growth of the peptide therapeutics market. In January 2020, researchers from The Chaim Sheba Medical Center, Israel, reported that high fructose consumption induced metabolic changes and dysbiosis in rats and that metabolic changes are probably independent of a specific microbiome profile.
Parenteral sub segment in the route of administration segment in global peptide therapeutics market was valued at US$ 16,416.8 Mn in 2018 and is expected to reach US$ 40,790.6 Mn by 2027 at a CAGR of 10.5% during the forecast period.
Market Trends/Key Takeaways
The market is witnessing increasing adoption of new platforms that develop next-generation protein or peptide therapeutics. For instance, in January 2020, Xenetic Biosciences, Inc. announced publication of the data from the completed Phase 1/2 clinical study of SHP656 ("PSA-recombinant Factor VIII", "PSA-rFVIII") in the journal Haemophilia. The study used Xenetic's PolyXen technology – a patent-protected platform technology for creating next-generation protein or peptide therapeutics.
The market is also witnessing increasing M&A activities. For instance, in January 2020, Almirall, S.A. acquired Bioniz Therapeutics Inc., a clinical stage biopharmaceutical company that develops first-in-class peptide treatments for immuno-inflammatory diseases.
Global Peptide Therapeutics Market: Competitive Landscape
Major players operating in the global peptide therapeutics market include, AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.
Global Peptide Therapeutics Market: Key Developments
Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in October 2019, PolyPeptide Group collaborated with the Green Chemistry and Enabling Technologies Team of IBMM (Institut des Biomolécules Max Mousseron), for R&D greener solutions to produce synthetic peptides.
Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.
Peptide therapeutics continue to expands its application by broaden molecular diversity and by engineering enhanced pharmaceutical properties. Research continues to expand the potential range of peptide-based pharmaceuticals to focus on treatment targets. However, large number of peptide targets shown in its early-stage of clinical trials or in preclinical models of disease, such as a melanocortin 4 receptor (MC4R) agonist, may reduce the body weight of patients with genetic obesity syndromes.
Furthermore, increasing development are in progress to extend the half-life period of peptide drugs; to improve the oral bioavailability of peptide therapeutics and to enhance the Central Nervous System (CNS) availability of peptide drugs through nanoparticle delivery in the indications such as Alzheimer’s disease and stroke.
Market players are engaged in developing novel and innovative peptide therapeutics drugs in order to offer tailored solution to target patient by increasing biocompatibility and potent therapeutic effects. Increasing prevalence of cancer and diabetes mellitus is projected to drive growth of the peptide therapeutics market over the forecast period. Also, clinical development in the field of peptide reflects it as an effective tool for molecular pharmacology.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.